(MedPage Today) — SAN FRANCISCO — Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer led to a significant improvement in overall response rate (ORR), according…
Source link : https://www.medpagetoday.com/meetingcoverage/ascogi/119298
Author :
Publish date : 2026-01-06 19:27:00
Copyright for syndicated content belongs to the linked Source.
